

Fasiha Kanwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/820699/publications.pdf>

Version: 2024-02-01

138
papers

8,297
citations

61984

43
h-index

49909

87
g-index

139
all docs

139
docs citations

139
times ranked

9870
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999â€“2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 223-225.e3. | 4.4 | 5 |
| 2 | Risk factors for HCC in contemporary cohorts of patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 997-1005. | 7.3 | 36 |
| 3 | Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. <i>Liver Transplantation</i> , 2023, 29, 15-25. | 2.4 | 2 |
| 4 | Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 9-18. | 4.4 | 58 |
| 5 | Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARSâ€“CoVâ€“2 Infection. <i>Liver Transplantation</i> , 2022, 28, 127-130. | 2.4 | 1 |
| 6 | Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. <i>Journal of Hepatology</i> , 2022, 76, 294-301. | 3.7 | 20 |
| 7 | Clinical Factors Associated With Lack of Serological Response to SARSâ€“CoVâ€“2 Messenger RNA Vaccine in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 123-126. | 2.4 | 25 |
| 8 | Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299. | 7.3 | 26 |
| 9 | Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 75, 1420-1428. | 7.3 | 65 |
| 10 | Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 76, 251-274. | 7.3 | 18 |
| 11 | AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. <i>Hepatology</i> , 2022, 76, 819-853. | 7.3 | 56 |
| 12 | Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62. | 3.7 | 19 |
| 13 | Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. <i>Clinical Transplantation</i> , 2022, , e14646. | 1.6 | 1 |
| 14 | Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , . | 4.4 | 0 |
| 15 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , . | 4.4 | 0 |
| 16 | Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. <i>Hepatology</i> , 2022, 76, 546-548. | 7.3 | 4 |
| 17 | Reply. <i>Hepatology</i> , 2022, 76, E50-E50. | 7.3 | 0 |
| 18 | Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 5695. | 3.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313. | 1.6 | 10 |
| 20 | Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2981-2991. | 2.3 | 10 |
| 21 | Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1443-1450.e6. | 4.4 | 13 |
| 22 | Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2439-2451. | 2.3 | 23 |
| 23 | Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 912-916. | 2.3 | 19 |
| 24 | Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 61-71.e15. | 4.4 | 159 |
| 25 | Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2021, 74, 477. | 3.7 | 0 |
| 26 | Unconscious Bias in Peer Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 419-420. | 4.4 | 13 |
| 27 | Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , 2021, 17, 308-308. | 2.1 | 0 |
| 28 | On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870. | 4.4 | 33 |
| 29 | Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 701-711. | 3.7 | 1 |
| 30 | Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424. | 8.1 | 11 |
| 31 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , . | 4.4 | 0 |
| 32 | Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. <i>Gastroenterology</i> , 2021, 161, 333-335. | 1.3 | 0 |
| 33 | Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172. | 8.6 | 30 |
| 34 | Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 949. | 5.1 | 35 |
| 35 | Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. <i>Microbial Ecology</i> , 2021, , 1. | 2.8 | 10 |
| 36 | NAFLD and HCC: Time to Bridge the Gap. <i>Hepatology</i> , 2021, 74, 2336-2338. | 7.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412. | 3.0 | 7 |
| 38 | Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8. | 1.3 | 58 |
| 39 | Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. <i>Transplant International</i> , 2021, 34, 1971-1983. | 1.6 | 2 |
| 40 | Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. <i>Hepatology</i> , 2021, 74, 3316-3329. | 7.3 | 75 |
| 41 | Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822. | 3.4 | 25 |
| 42 | Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669. | 1.3 | 229 |
| 43 | Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. <i>Clinical Transplantation</i> , 2021, , e14544. | 1.6 | 1 |
| 44 | Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. <i>Hepatology</i> , 2020, 71, 44-55. | 7.3 | 188 |
| 45 | Integrated Model for Patient-Centered Advanced Liver Disease Care. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1015-1024. | 4.4 | 19 |
| 46 | Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 808-819. | 7.3 | 170 |
| 47 | Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. <i>Antiviral Research</i> , 2020, 174, 104698. | 4.1 | 10 |
| 48 | Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1858-1866.e6. | 4.4 | 11 |
| 49 | Covering the Year in CGH: 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3-10. | 4.4 | 3 |
| 50 | The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. <i>Gastroenterology</i> , 2020, 159, 1184-1185. | 1.3 | 2 |
| 51 | Trends in Outcomes for Marginal Allografts in Liver Transplant. <i>JAMA Surgery</i> , 2020, 155, 926. | 4.3 | 48 |
| 52 | Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2020, 73, 1579-1580. | 3.7 | 0 |
| 53 | Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 1425-1433. | 3.7 | 81 |
| 54 | Aggressive utilization of liver allografts: Improved outcomes over time. <i>Clinical Transplantation</i> , 2020, 34, e13860. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | A learning curve in using orphan liver allografts for transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13821. | 1.6 | 0 |
| 56 | Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. <i>Transplant International</i> , 2020, 33, 925-935. | 1.6 | 3 |
| 57 | Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. <i>JAMA Network Open</i> , 2020, 3, e2021173. | 5.9 | 15 |
| 58 | Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. <i>JAMA Network Open</i> , 2020, 3, e2023780. | 5.9 | 45 |
| 59 | Risk Factors for Cirrhosis in Contemporary Hepatology Practices—Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. <i>Gastroenterology</i> , 2020, 159, 376-377. | 1.3 | 32 |
| 60 | Early Impact of COVID-19 on Solid Organ Transplantation in the United States. <i>Transplantation</i> , 2020, 104, 2221-2224. | 1.0 | 68 |
| 61 | Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 628-640. | 2.0 | 2 |
| 62 | The HCV Treatment Cascade: Race Is a Factor to Consider. <i>Journal of General Internal Medicine</i> , 2019, 34, 1949-1951. | 2.6 | 5 |
| 63 | Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2019, 71, 638-639. | 3.7 | 1 |
| 64 | Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726. | 1.9 | 34 |
| 65 | Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1470-1477. | 2.3 | 3 |
| 66 | AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157. | 1.3 | 90 |
| 67 | Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?". <i>Journal of Hepatology</i> , 2019, 70, 1301-1302. | 3.7 | 0 |
| 68 | Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. <i>Nutrients</i> , 2019, 11, 613. | 4.1 | 48 |
| 69 | Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 530-532. | 0.4 | 27 |
| 70 | Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647. | 3.7 | 101 |
| 71 | Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 1787-1797. | 7.3 | 92 |
| 72 | Nutrition in Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2019, 23, 99-114. | 2.1 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. <i>Journal of Viral Hepatitis</i> , 2019, 26, 596-602. | 2.0 | 67 |
| 74 | Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8. | 4.4 | 24 |
| 75 | Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 98-106. | 0.4 | 36 |
| 76 | Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1677-1678. | 4.4 | 63 |
| 77 | Hepatology in a changing health care landscape: A call for health services research. <i>Hepatology</i> , 2018, 68, 1154-1162. | 7.3 | 0 |
| 78 | Patient-reported outcomes in cirrhosis: A scoping review of the literature. <i>Hepatology</i> , 2018, 67, 2375-2383. | 7.3 | 62 |
| 79 | Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 459-461. | 4.4 | 3 |
| 80 | Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. <i>BMC Medical Research Methodology</i> , 2018, 18, 1. | 3.1 | 390 |
| 81 | Houston Consensus Conference on Testing for <i>Helicobacter pylori</i> Infection in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 992-1002.e6. | 4.4 | 189 |
| 82 | Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10. | 4.4 | 21 |
| 83 | A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. <i>Health Services Research</i> , 2018, 53, 2547-2566. | 2.0 | 8 |
| 84 | Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 252-259. | 4.4 | 47 |
| 85 | Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095. | 7.3 | 50 |
| 86 | Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1828-1837.e2. | 1.3 | 490 |
| 87 | Implementation of a Population-Based Cirrhosis Identification and Management System. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1182-1186.e2. | 4.4 | 11 |
| 88 | Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. <i>Gastroenterology</i> , 2018, 155, 719-729.e4. | 1.3 | 81 |
| 89 | Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1207-1217.e4. | 4.4 | 71 |
| 90 | The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1180-1185. | 2.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. <i>Current Hepatology Reports</i> , 2017, 16, 26-32. | 0.9 | 0 |
| 92 | Hepatitis C and Risk of Nonhepatic Malignancies. <i>Clinics in Liver Disease</i> , 2017, 21, 543-554. | 2.1 | 15 |
| 93 | The Top Five Reasons You Should Publish in <i>Clinical Gastroenterology and Hepatology</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 164-165. | 4.4 | 2 |
| 94 | Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients". <i>Journal of Hepatology</i> , 2017, 67, 884-885. | 3.7 | 1 |
| 95 | Reply to: "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection". <i>Journal of Hepatology</i> , 2017, 67, 886-887. | 3.7 | 1 |
| 96 | Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2017, 153, 996-1005.e1. | 1.3 | 680 |
| 97 | Global epidemiology and burden of HCV infection and HCV-related disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 122-132. | 17.8 | 317 |
| 98 | Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 526-533. | 2.3 | 27 |
| 99 | Anniversary Tribute From the Editors of <i>Clinical Gastroenterology and Hepatology</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1823-1827. | 4.4 | 0 |
| 100 | Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2713-2718. | 2.3 | 28 |
| 101 | Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 273-281.e1. | 4.4 | 106 |
| 102 | Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 355-362. | 3.7 | 104 |
| 103 | Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 310-312. | 4.4 | 12 |
| 104 | Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. <i>Gastroenterology</i> , 2017, 152, 812-820.e5. | 1.3 | 339 |
| 105 | Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788. | 7.3 | 83 |
| 106 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 487-488. | 4.4 | 0 |
| 107 | Quality of Care in the Cirrhotic Patient. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e166. | 2.5 | 18 |
| 108 | Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2016, 63, 291-299. | 5.8 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1678-1680. | 4.4 | 23 |
| 110 | Collaborative Care for Depression in Chronic Hepatitis C Clinics. <i>Psychiatric Services</i> , 2016, 67, 1076-1082. | 2.0 | 7 |
| 111 | Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1714-1720. | 2.3 | 72 |
| 112 | Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 191-202.e4. | 4.4 | 126 |
| 113 | Trends in the Burden of Nonalcoholic Fatty Liver Disease in United States Cohort of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 301-308.e2. | 4.4 | 136 |
| 114 | Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 124-131.e1. | 4.4 | 471 |
| 115 | Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2030-2037. | 2.3 | 3 |
| 116 | Use of Hyatt's Law, R Criteria, and nR Criteria to Predict Acute Liver Failure or Transplantation in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2015, 148, 452. | 1.3 | 3 |
| 117 | Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 594-601.e1. | 4.4 | 215 |
| 118 | Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. <i>American Journal of Gastroenterology</i> , 2015, 110, 10-14. | 0.4 | 110 |
| 119 | Pay for Performance in Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2042-2047. | 4.4 | 8 |
| 120 | Response to Li et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 774. | 0.4 | 0 |
| 121 | Why We Should Be Willing to Pay for Hepatitis C Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1711-1713. | 4.4 | 10 |
| 122 | Decreasing Mortality in Patients Hospitalized With Cirrhosis. <i>Gastroenterology</i> , 2015, 148, 897-900. | 1.3 | 12 |
| 123 | The Art and Science of Managing Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2029-2030. | 4.4 | 1 |
| 124 | Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. <i>Hepatology</i> , 2014, 60, 1871-1878. | 7.3 | 67 |
| 125 | New Diagnosis of Chronic Pancreatitis: Risk of Missing an Underlying Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1824-1830. | 0.4 | 52 |
| 126 | Improving Quality of Health Care for Patients With Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 1204-1207. | 1.3 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | The End of Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 533-536. | 4.4 | 26 |
| 128 | Primary Prophylaxis of Variceal Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 783-794. | 2.2 | 4 |
| 129 | Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1427-1435. | 0.4 | 84 |
| 130 | The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs. <i>American Journal of Gastroenterology</i> , 2014, 109, 934-940. | 0.4 | 42 |
| 131 | Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383. | 4.4 | 16 |
| 132 | Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1143-1150.e1. | 4.4 | 85 |
| 133 | A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. <i>Gastroenterology</i> , 2014, 146, 1249-1255.e1. | 1.3 | 156 |
| 134 | Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 327-333.e1. | 4.4 | 11 |
| 135 | Improving quality of care in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2013, 2, 123-124. | 2.1 | 5 |
| 136 | Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1342-1359.e2. | 4.4 | 634 |
| 137 | The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. <i>Gastroenterology</i> , 2012, 143, 70-77. | 1.3 | 133 |
| 138 | An Explicit Quality Indicator Set for Measurement of Quality of Care in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 709-717. | 4.4 | 109 |